CN107028874A - External-applied ointment - Google Patents

Abstract

The invention discloses a kind of external-applied ointment.The ointment composition, including erythromycin spongaion and stoma skin care powder.The mass volume ratio of erythromycin and stoma skin care powder in the erythromycin spongaion is 12.5mg：0.1ml‑0.3ml.In the erythromycin spongaion, the weight/mass percentage composition of erythromycin is 0.5%.The patient that the ointment composition that the present invention is provided is very suitable for skin injury uses, and the patient for being especially suitable for early stage mid-term incontinence dermatitis and the shallow skin injury of table uses, with the effect for treating and promoting local wound healing.Ointment composition formula is simple, and sensitization is low, and effect is notable.

Description

topical ointment

technical field

The invention belongs to the field of medicine and relates to an external ointment.

Background technique

Most of the products currently on the market for the treatment of damaged skin are traditional Chinese medicine preparations. Its formula has many ingredients, and the procurement of ingredients is likely to be affected by different places of production; in addition, its preparation process is cumbersome, and its purification needs to be optimized, which is not conducive to the use of patients with sensitive constitutions. In terms of western medicine, there is no external medicine that combines treatment and protection for early and mid-term incontinence dermatitis, and is easy to use and has a significant effect. Incontinent dermatitis can occur in clinics, communities, and family care, especially in elderly patients and long-term bedridden patients who have lost their mobility. The pH of healthy human skin is between 4-6, which is acidic. pH plays an important role in the acidic outer membrane of the skin barrier. This acidic mantle helps regulate the skin's resident bacteria (skin microbes) and also ensures optimal stratum corneum-binding barrier function. IAD is prone to occur when the local stratum corneum barrier function is impaired due to increased skin pH due to frequent defecation and defecation stimulation. In severe cases, it can lead to secondary infection, which not only brings pain to patients, prolongs hospital stay, wastes medical resources, but also increases unnecessary nursing workload. At present, for the prevention and treatment of incontinence dermatitis, in addition to avoiding and removing adverse stimuli and increasing the number of times of turning over, most of the methods are only local dressing changes, local dressings or the application of traditional Chinese medicine preparations, and local oxygen therapy. The operation is complicated. Nursing workload is heavy, and it takes a long time for the patient's damaged skin to heal. Thereby, it is urgent to develop a kind of external ointment applicable to incontinence dermatitis.

Contents of the invention

The object of the present invention is to provide an external ointment, which can effectively prevent the occurrence of dermatitis, especially incontinent dermatitis, especially for the treatment of early and mid-term incontinent dermatitis.

The ointment composition provided by the invention includes erythromycin eye ointment and stoma skin care powder.

The above-mentioned ointment composition may only consist of erythromycin eye ointment and stoma skin care powder.

In the above ointment composition, the mass volume ratio of erythromycin in the erythromycin eye ointment to stoma skin care powder is 12.5mg: 0.1ml-0.3ml, specifically 12.5mg: 0.1ml, 12.5mg: 0.2 ml or 12.5mg: 0.3ml.

In the erythromycin eye ointment, the mass percent content of erythromycin is 0.5%.

The erythromycin eye ointment used in the ointment composition can be erythromycin eye ointment with a mass percentage of 0.5% erythromycin that can be purchased from public channels, such as Beijing Shuangji Pharmaceutical Co., Ltd. The erythromycin eye ointment is an oily ointment antibiotic belonging to macrolide antibiotics. It has certain antibacterial activity against staphylococcus, various streptococci, legionnaires' disease, mycoplasma, chlamydia, etc. The auxiliary materials are yellow vaseline and liquid paraffin. Its excipients have no bactericidal ability, but its non-hydrophilic and non-absorbable properties enable it to form a film on the skin, making it difficult for water molecules to evaporate and lose. And block the bacteria from the outside world, thereby reducing the possibility of re-infection.

The stoma skin care powder used is a skin care powder commonly used in stoma care, and its main component is sodium carboxymethylcellulose, specifically composed of sodium carboxymethylcellulose, gelatin and colloid, which can be purchased from Converse (China ) Medical Supplies Co., Ltd., item number: 25510, capacity: 28.3g. Ostomy skin care powder can absorb exudate to form a soft gel protective film, which can be pasted on the skin wound surface to block sweat, urine and other dirt from re-wetting and stimulating the skin, and can reduce friction on local wounds, making lesions Do not continue to expand. It can also effectively protect the skin of the affected area, accelerate tissue healing, and avoid secondary infection.

The preparation method of the ointment composition comprises: mixing the erythromycin eye ointment and stoma skin care powder evenly under aseptic conditions.

When the ointment composition is actually used, an appropriate amount can be applied according to the patient's wound area. For the treatment of local skin damage caused by incontinence dermatitis, the following operations can be carried out: After cleaning the local wound with sterile physiological saline, gently dip the excess water around the wound with a sterile cotton swab, and then use a sterile cotton swab to mix the Gently apply the ointment to the local skin wound, and the area of the ointment should be greater than 2cm around the local rash or skin damage. Apply the ointment composition provided by the invention at least 5 times a day. Before each application of the ointment composition, the previously applied ointment composition needs to be wiped off with a cleansing wet towel, and then the local skin wound is cleaned with sterile physiological saline, and then the ointment composition provided by the invention is applied. If the patient does not defecate, the above care should be given to change the dressing according to the dryness and recovery of the patient's local wound every time he turns over. Pay attention to aseptic operation when applying the ointment composition, and require gentle movements. It is usually applied with a sterile cotton swab. Application of any dressing to the local skin is not required after application of the ointment composition. For patients with grade 2 IAD, before changing the dressing for the first time, due to the damage of the local skin protective layer, the fecal dirt on the local skin of the patient should be cleaned by lightly dipping to reduce adverse irritation to the local skin The area of skin damage caused by it increases.

In addition, the application of the ointment composition provided by the present invention in the preparation of products for preventing and/or treating skin damage also belongs to the protection scope of the present invention.

In the above application, the skin damage is caused by incontinent dermatitis.

In addition, the present invention also claims an ointment composition composed of erythromycin eye ointment and sodium carboxymethylcellulose.

In the ointment composition, the mass volume ratio of erythromycin in the erythromycin eye ointment to carboxymethylcellulose sodium is 12.5mg: 0.1ml-0.3ml;

In the erythromycin eye ointment, the mass percent content of erythromycin can be specifically 0.5%.

In addition, the application of the above two ointment compositions provided by the present invention in the preparation of products for preventing and/or treating skin damage also belongs to the protection scope of the present invention.

In the above application, the skin damage is caused by incontinent dermatitis.

In addition, the present invention also claims the application of erythromycin and sodium carboxymethylcellulose in the preparation of products for preventing and/or treating skin damage. In the above application, the skin damage is caused by incontinent dermatitis. The mass volume ratio of the erythromycin to sodium carboxymethylcellulose is 12.5mg: 0.1ml-0.3ml; the mass percentage of the erythromycin in the preparation of the product for preventing and/or treating skin damage can be 0.5%.

The ointment composition provided by the invention has a simple formula and low sensitization, and is very suitable for patients with damaged skin, especially for patients with incontinence dermatitis and superficial skin damage in the early and middle stages, and has the effect of treating and promoting local wound healing , shortened the healing time of local wounds and had no side effects; after nursing and dressing observation, the patient’s local wounds healed quickly; the ointment was prepared in proportion in advance, which obviously economically and effectively controlled the amount of ointment and did not cause too much waste of powder; The operation method is simple and easy to grasp; and because the mixed ointment is transparent and light yellow, it is convenient to observe the healing condition of the local wound each time, and greatly saves the time for each dressing change. Even for some IAD I patients, the local skin can completely return to normal after nursing and changing the dressing only 1-2 times, which greatly improves the quality of nursing work and reduces the psychological burden and discomfort of the patients.

detailed description

The present invention will be further described below in conjunction with specific examples, but the present invention is not limited to the following examples. The methods are conventional methods unless otherwise specified. The raw materials can be obtained from open commercial channels unless otherwise specified. The erythromycin ointment used in the following examples was purchased from Beijing Shuangji Pharmaceutical Co., Ltd., and the specification was 0.5%, that is, the mass percentage of erythromycin in each erythromycin ointment was 0.5%. Containing 12.5 mg of erythromycin, the weight of each erythromycin eye ointment is 2.5 g. The auxiliary materials are: yellow vaseline, liquid paraffin. The stoma skin care powder used was purchased from Kangweide (China) Medical Supplies Co., Ltd., item number: 25510, filling volume: 28.3g, and the product name was Stomahesive Protective Powder.

Embodiment 1,

Take 3 sticks of erythromycin eye ointment and put them in a clean container, then add 0.3ml of stoma skin care powder (take it with a disposable syringe needle. Discard the needle and needle plug and stick it on the nipple of the syringe needle with adhesive tape to make it Keep the sealed state, when measuring the stoma skin care powder, you can directly squeeze the stoma skin care powder into the needle tube of the syringe to the required scale. ), fully stir evenly with a sterile cotton swab, and obtain the ointment composition I provided by the invention. Make sure that each patient is ready to use, and it is forbidden to reuse a bottle of ointment for different patients.

Embodiment 2,

Following the same steps as in Example 1, only the amount of stoma skin care powder was replaced by 0.6 ml to obtain ointment composition II provided by the present invention.

Embodiment 3,

Following the same steps as in Example 1, only the amount of stoma skin care powder was replaced by 0.9 ml to obtain ointment composition III provided by the present invention.

Embodiment 4,

According to the same steps as in Example 1, only 0.3 ml of stoma skin care powder was replaced with 0.3 ml of sodium carboxymethylcellulose to obtain ointment composition IV provided by the present invention.

Application of the ointment composition obtained in embodiment 5, embodiment 1-4 in the treatment of skin damage caused by incontinence dermatitis

1 clinical data

Sixty patients with incontinence dermatitis in the cardiac surgery intensive care unit from January 2014 to June 2016 were randomly divided into observation group and control group.

Observation group a: 30 cases, 15 males and 15 females; aged 51-85 years, with an average age of 68.9 years. IAD classification: 10 cases of grade Ⅰ, 20 cases of grade Ⅱ, 0 cases of grade Ⅲ.

Observation group b: 30 cases, 15 males and 15 females; aged 51-85 years, with an average age of 68.9 years. IAD classification: 10 cases of grade Ⅰ, 20 cases of grade Ⅱ, 0 cases of grade Ⅲ.

The control group consisted of 30 cases, including 18 males and 12 females; aged 52-80 years, with an average age of 67.4 years. IAD classification: 11 cases of grade I, 19 cases of grade II, and 0 cases of grade III.

There was no history of allergy to erythromycin in the two groups. Moreover, under the condition that the general principles of medical treatment are the same, there is no statistically significant difference in general information such as age, gender, underlying disease, and nutritional status between the two groups of patients, and they are comparable.

2 Operation method

2.1. Control group:

Use skin care powder care alone to change dressings.

The specific method is: after cleaning the perianal skin, first use sterile saline to clean the local wound, then use a sterile cotton swab to gently dip the excess water in the wound, and then use skin care powder (simple ostomy powder) to separate the wound from the skin Spray on the surface of the local wound at a distance of 5-10cm, and the spraying area should fully cover the wound area or skin rash.

2.2. Observation group a:

Use the ointment composition obtained in Example 1 of the present invention to carry out nursing and dressing change.

The specific method is: after cleaning the local wound with sterile normal saline, gently dip the excess water around the wound with a sterile cotton swab, and then gently apply the mixed ointment to the local skin wound with a sterile cotton swab. 2cm around the rash or skin damage area. Smear embodiment 1 gained ointment composition one day at least five times. Before each application of the mixed ointment, it is necessary to wipe off the previously applied ointment with a cleansing wet towel, then clean the local skin wound with sterile physiological saline, and then apply the ointment composition obtained in Example 1. If the patient does not defecate, the above care should be given to change the dressing according to the dryness and recovery of the patient's local wound every time he turns over. Pay attention to aseptic operation when applying the ointment composition, and require gentle movements. It is usually applied with a sterile cotton swab. Application of any dressing to the topical skin is not required after application of the ointment composition. For patients with grade 2 IAD, before changing the dressing for the first time, due to the damage of the local skin protective layer, the fecal dirt on the local skin of the patient should be cleaned by lightly dipping to reduce adverse irritation to the local skin The area of skin damage caused by it increases.

Observation group b:

Use ointment composition IV obtained in Example 4 of the present invention to carry out nursing and dressing change.

The specific method is the same as that of observation group a, only ointment composition I is replaced by ointment composition IV.

3 Observation indicators

3.1 IAD grading standard level Ⅰ: the skin is intact, with mild redness and discomfort. Grade II: Moderate redness of the skin, exfoliation of the skin, small blisters or damage to a small area of the skin, accompanied by pain or discomfort. Grade Ⅲ: dark red or dark red skin, large areas of damaged skin exfoliation, blisters and oozing.

3.2 Observation and comparison indicators

3.2.1 Compare the IAD treatment effect, local wound healing time and each nursing dressing change operation time between the two groups.

3.2.2 Evaluation criteria for the treatment effect of IAD: cure: 3-5 days of nursing and dressing change, the skin completely returns to normal; improvement: 5-7 days of nursing and dressing change, skin flushing improves or local wounds heal; invalid: nursing and dressing change 7 For more than a day, there is no improvement or aggravation of the local skin.

4 statistical processing

Statistical analysis of data was carried out using SPSS15.0 statistical software.

5 results

Table 1. Comparison of IAD treatment effect among three groups of patients

Table 2. Comparison of IAD healing time and nursing dressing change time in three groups of patients

In the observation group a, the ointment composition I obtained in Example 1 was replaced with the ointment composition II or III obtained in Example 2 or 3, and the obtained effect was not substantially different from the above, so it will not be repeated. Although the effect of the ointment composition IV used in observation group b is not as good as that in observation group a, it also has a good effect of treating and promoting local wound healing.

It can be seen from the above that the ointment composition provided by the present invention is very suitable for patients with damaged skin, especially for patients with early and mid-term incontinence dermatitis and superficial skin damage, and has the effect of treating and promoting local wound healing. The ointment composition has simple formula, low allergenicity and remarkable effect.

Claims (10)

1. An ointment composition, comprising erythromycin eye ointment and stoma skin care powder. 2. The ointment composition according to claim 1, characterized in that: the mass volume ratio of erythromycin in the erythromycin eye ointment to stoma skin care powder is 12.5mg: 0.1ml-0.3ml. 3. The ointment composition according to claim 1 or 2, characterized in that: in the erythromycin eye ointment, the mass percentage of erythromycin is 0.5%. 4. An ointment composition consisting of erythromycin ophthalmic ointment and sodium carboxymethylcellulose. 5. The ointment composition according to claim 4, characterized in that: the mass volume ratio of erythromycin in the erythromycin eye ointment to sodium carboxymethylcellulose is 12.5mg: 0.1ml-0.3ml; In the erythromycin eye ointment, the mass percent content of erythromycin is specifically 0.5%. 6. The application of the ointment composition described in any one of claims 1-5 in the preparation of products for preventing and/or treating skin damage. 7. The application according to claim 6, characterized in that: the skin damage is caused by incontinence dermatitis. 8. Application of erythromycin and sodium carboxymethylcellulose in the preparation of products for preventing and/or treating skin damage. 9. The application according to claim 8, characterized in that: the skin damage is caused by incontinence dermatitis. 10. The application according to claim 8 or 9, characterized in that: the mass volume ratio of the erythromycin to sodium carboxymethylcellulose is 12.5mg: 0.1ml-0.3ml; The mass percentage content of the erythromycin in the preparation of the product for preventing and/or treating skin damage is specifically 0.5%.